We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of these patients. Forty patients received modified FOLFIRI: irinotecan 180 mg m(-2), day 1; folinic acid, 200 mg m(-2); and 5-fluorouracil: as a 400 mg m(-2) bolus, days 1 and 2, and a 48-h continuous infusion 1200 mg m(-2), from day 1. Treatment was repeated every 2 weeks, with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen (47.5%) of 40 patients achieved an objective response; 13 (33%) underwent resection. After a median follow-up of 56 months, median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times.

Barone, C. A., Nuzzo, G., Cassano, A., Basso, M., Schinzari, G., Giuliante, F., D'argento, E. G., Trigila, N., Astone, A., Pozzo, C., Final analysis of colorectal cancer patients treated with irinotecan and5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases, <<BRITISH JOURNAL OF CANCER>>, 2007; 97 (8): 1035-1039. [doi:10.1038/sj.bjc.6603988] [http://hdl.handle.net/10807/14744]

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases

Barone, Carlo Antonio;Nuzzo, Gennaro;Cassano, Alessandra;Basso, Michele;Schinzari, Giovanni;Giuliante, Felice;D'Argento, Ettore Giovanni;Trigila, Nunziatina;Astone, Antonio;Pozzo, Carmelo
2007

Abstract

We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of these patients. Forty patients received modified FOLFIRI: irinotecan 180 mg m(-2), day 1; folinic acid, 200 mg m(-2); and 5-fluorouracil: as a 400 mg m(-2) bolus, days 1 and 2, and a 48-h continuous infusion 1200 mg m(-2), from day 1. Treatment was repeated every 2 weeks, with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen (47.5%) of 40 patients achieved an objective response; 13 (33%) underwent resection. After a median follow-up of 56 months, median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times.
Inglese
Barone, C. A., Nuzzo, G., Cassano, A., Basso, M., Schinzari, G., Giuliante, F., D'argento, E. G., Trigila, N., Astone, A., Pozzo, C., Final analysis of colorectal cancer patients treated with irinotecan and5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases, <>, 2007; 97 (8): 1035-1039. [doi:10.1038/sj.bjc.6603988] [http://hdl.handle.net/10807/14744]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/14744
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 90
social impact